Antibiotic Prophylaxis Does Not Prevent Hospital-Acquired Infection in Patients With Cirrhosis
Researchers evaluate whether antibiotic use in patients with decompensated cirrhosis and without infection prevented hospital-acquired infection.
Researchers evaluate whether antibiotic use in patients with decompensated cirrhosis and without infection prevented hospital-acquired infection.
The NDA is supported by two 2 positive interim analyses from the phase 3 REGENERATE trial that included patients with biopsy-proven stage 2 or 3 liver fibrosis due to NASH.
Researchers evaluated oral health as a determinant of 3-month hospitalizations in compensated or decompensated outpatients with cirrhosis.
Researchers compared spleen stiffness vs liver stiffness measurements for predicting liver decompensation and survival in cirrhosis.
Researchers investigated the rate and risk for fractures and postfracture mortality among patients with alcohol-related cirrhosis.
Researchers investigated the relationship between proton pump inhibitor exposure and infection, decompensation, and all-cause mortality in liver cirrhosis.
Researchers compared maternal and perinatal outcomes in US pregnant patients with cirrhosis, noncirrhotic chronic liver disease (CLD), and without CLD.
The natural history of cirrhosis is significantly affected by the increasing prevalence of infections, with strategies for prevention and treatment difficult to compose.
Researchers evaluated the rates of and factors associated with referral, wait-listing, and receipt of liver allografts.